Recent Changes in Discretionary Denials of Drug Patent Challenges

Дата публикации: 09-09-2026 22:35:59

Recent policy shifts at the U.S. Patent and Trademark Office (USPTO) have sharply limited the use of two administrative pathways for patent reviews, inter partes review (IPR) and post-grant review (PGR). Congress created these administrative pathways to provide a faster and less costly way to challenge weak patents. Recently, the USPTO has expanded the use of “discretionary denials,” invoking a new “settled expectations” rationale that blocks IPR petitions for patents more than about six years old. From May to September 2025, 60% of 506 requests for discretionary denial were granted, triple historical levels, including one-third involving drug patents. These changes are especially consequential for biologic drugs, where large “patent thickets” can delay biosimilar entry and sustain high drug prices. Additional procedural reforms, such as reducing allowable brief length by 60% and consolidating all institution decisions under the Director, further constrain challengers and reduces transparency. Together, these policies undermine the congressional purpose of ensuring that invalid patents do not block competition. Congress should clarify when discretionary denials are appropriate and prohibit non-merits-based rationales like “settled expectations” to preserve effective patent oversight and timely access to affordable medicines.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	The Reliability Response to Patent Law’s AI Challenges	0	5.75	09-09-2026
2	FY2026 Patent Data Update: Grants, Publications, and Cross-Border Inventors	0	25.46	02-10-2026
3	Method or Molecule: Judge Dyk Dissents from En Banc Denial in Teva v. Lilly	0	8.62	01-10-2026
4	Clear but Impossible: Satius v. Samsung Moves Inoperable Claims from Indefiniteness to Enablement	0	9.88	01-10-2026
5	Amicus Brief on Nonconsensual Nondebtor Releases in Chapter 11 Bankruptcy Reorganizations (Harrington v. Purdue Pharma)	0	9.1	05-10-2026
6	IP — Federal Circuit Tightens the Grace Period: What a Private Sale Means for Your Patent Rights	0	8.42	01-10-2026
7	US exempts select Indian specialty drugs from 100% tariff	0	13.6	29-09-2026
8	Les vents sont redevenus porteurs pour les biotechs	0	10.98	03-10-2026
9	Цена инноваций: как совместить защиту патентов и доступность лекарств	0	7.59	28-09-2026
10	Justices Skip 2 Patent Cases, 1 Trade Secret Dispute	0	12.2	05-10-2026

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.63. Источник: scholarship.law.duke.edu.